XWELL, Inc. (XWEL) Q4 2023 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals ongoing challenges in achieving profitability, high operating costs, and reliance on air travel. Despite revenue growth and cost-cutting measures, the company faces significant operating losses. Expansion plans carry risks, and the market is highly competitive. The Q&A section highlights concerns about management's transparency and financial restatements. Overall, the negative financial health and uncertainties overshadow the revenue growth, leading to a negative sentiment.
Key Financial Performance
Total Revenue $30.1 million, a decrease from $43.9 million in the prior year, primarily due to operational adjustments and cost management efforts.
XpresSpa Revenue $19.5 million, contributing to the overall revenue growth of approximately 39% year-over-year.
XpresTest Revenue $9.9 million, which includes revenue from the biosurveillance partnership and HyperPointe business.
Naples Wax Revenue $650,000, with a year-over-year growth of approximately 3%.
Total Cost of Sales $26.4 million, a decrease of approximately 40% year-over-year from $43.9 million, due to cost-cutting measures.
Salaries, General and Administrative Expenses $20.9 million, down from $31.2 million in the prior year, reflecting the company's cost management initiatives.
Operating Loss $28.2 million, an improvement from an operating loss of $31.2 million in the prior year, indicating progress towards profitability.
Net Loss Attributable to XWELL $28 million, compared to a net loss of approximately $32.7 million in the prior year, showing a reduction in losses.
Cash and Cash Equivalents $8.4 million at year-end.
Marketable Securities $14.6 million at year-end.
Total Assets Approximately $26.6 million at year-end.
Long-term Debt No long-term debt reported.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
New Products: Introduction of proprietary stretching service in several XpresSpa locations, launched in September 2023, showing initial signs of growth. Deployment of autonomous massage chairs across most U.S. spa portfolio, representing nearly 10% of all XpresSpa services in 2023. Launch of autonomous manicure stations in Las Vegas, leading to 15% to 20% blended growth in service. Plans to launch Treat Studios, providing rentable space to established practitioners.
Market Expansion: Opened 11th international location in Abu Dhabi International Airport, exceeding expectations by 25%. Acquisition of Naples Wax for approximately $1.5 million, with plans to open three additional locations in Florida. Plans to expand XpresSpa brand into non-airport venues, starting with a location in New York City's Penn Station.
Operational Efficiencies: Achieved labor savings of 10% to 50% through staffing optimization and operational initiatives. Removed $11 million from the business in 2023 through headcount and process reductions. Total cost of sales decreased approximately 40% year-over-year.
Strategic Shifts: Focus on improving unit economics and profitability through operational efficiencies and wellness product deployment. Expansion of biosurveillance program with CDC, increasing funding and scope to an estimated $36.7 million.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Issues: The company faces risks related to the ongoing collaboration with the CDC for biosurveillance, which is subject to changes in government funding and regulations.
Competitive Pressures: XWELL is expanding its services and locations to remain competitive in the wellness and spa industry, particularly as it ventures outside traditional airport venues.
Supply Chain Challenges: The integration of new products and technologies into their spas may face supply chain disruptions, impacting operational efficiency and service delivery.
Economic Factors: The growth of air travel in Europe and the Middle East is crucial for XWELL's international expansion, making the company vulnerable to economic fluctuations in these regions.
Financial Reporting Risks: The company has experienced issues with financial reporting, including a misapplication of GAAP related to impairment charges, which could affect investor confidence and regulatory scrutiny.
Operational Efficiency: XWELL's efforts to optimize its cost structure and improve operational efficiencies may not yield the expected results, impacting profitability.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: XpresSpa delivered revenue growth of approximately 39% compared to 2022, with international spas achieving approximately 40% growth.
Acquisition of Naples Wax: Acquired Naples Wax for approximately $1.5 million, integrating three aesthetic centers, with plans to open three additional locations.
Expansion Plans: Plans to expand Naples Wax to approximately 10 locations by early 2025 and to take XpresSpa out of the airport with a new model in New York City's Penn Station.
Biosurveillance Program: Expanded collaboration with CDC, with program funding and scope increased to an estimated $36.7 million.
Cost Structure Optimization: Removed $11 million from the business in 2023, with an expected additional $5 million in savings in 2024.
New Initiatives: Launching Treat Studios later this year, providing rentable space for practitioners.
Technology Deployment: Deployed autonomous chairs and manicure stations, leading to 15%-20% growth in services.
Revenue Expectations: Total revenue for 2023 was approximately $30.1 million.
Operating Loss: Reported an operating loss of approximately $28.2 million for the year.
Cost of Sales: Total cost of sales decreased to $26.4 million from $43.9 million in the prior year.
Net Loss: Net loss attributable to XWELL was approximately $28 million.
Future Focus: Focused on improving execution, cost management, and operational processes.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchase Program: None
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Act Section
Audit Committee
City Penn
Florida
Middle East
Penn Station
Section Securities
Studios
XWELL
XpresSpa
York City
asset
cash
collaboration
commuter
country
determination
efficiency
funding
impairment charge
information error
labor saving
launch
mid
multipathogen
portfolio
practitioner
profitability
program United
reach
sale salary
spa transit
statement information
station
stretch
test
unit
XWEL Transcript
XWELL, Inc. (XWEL) Q3 2024 Earnings Call Transcript
Positive11-15
The earnings call summary reveals positive developments: a new partnership with Priority Pass, significant cost reductions, improved operating loss, and solid liquidity with no long-term debt. Despite some risks like regulatory and operational challenges, the strategic focus on expansion and cost management is promising. The Q&A section did not highlight significant analyst concerns, suggesting a generally positive sentiment. This, combined with a revenue increase and improved financial metrics, supports a positive stock price outlook over the next two weeks.
XWELL, Inc. (XWEL) Q4 2023 Earnings Call Transcript
Unknown4-16
The earnings call reveals ongoing challenges in achieving profitability, high operating costs, and reliance on air travel. Despite revenue growth and cost-cutting measures, the company faces significant operating losses. Expansion plans carry risks, and the market is highly competitive. The Q&A section highlights concerns about management's transparency and financial restatements. Overall, the negative financial health and uncertainties overshadow the revenue growth, leading to a negative sentiment.
XWELL, Inc. (XWEL) Q2 2023 Earnings Call Transcript
Neutral8-17
XWELL, Inc. (XWEL) Q4 2022 Earnings Call Transcript
Neutral4-24
XWEL Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
